FirstWord

Launched in Oct. 2025, K Pro is Owkin’s AI scientist for querying multimodal patient data and testing research hypotheses; AstraZeneca and Sanofi already signed up for multi-year licences.

The company said small-volume production of biologics in Kleinbasel is expected to be discontinued by the end of 2027 as R&D activities move to main Basel campus.

The startup's RNA-based platform is designed to insert whole therapeutic genes into the genome

The company said it is halting work on its lead programme TSC-101 and will instead focus on a pair of preclinical in vivo T cell receptor-engineered T cell candidates for solid tumours.

The company's AMT-130 filing follows the FDA's recent decision to accept a three-year analysis of Phase I/II data.

FirstWord highlights the key datasets and questions emerging from last weekend's European Society of Cardiology Congress in Munich.

MORRISVILLE, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challeng...

Patient-level matched analysis of real-world data demonstrated a significant 37% relative reduction in severe bleedingSignificant reductions in 24-hour chest tube drainage and red blood cell transfusi...

PALO ALTO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on devel...

Topline data from Phase 1/2 Cohort 1 of OPGx-BEST1 gene therapy program to be presented during investor conference call and webcast on September 9 at 8:00 a.m. ETFull clinical dataset and additional a...